{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:09:43Z","timestamp":1762513783480,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Beijing Major Science & Technology","award":["D090507043409008"],"award-info":[{"award-number":["D090507043409008"]}]},{"name":"Special Technology Innovation Funding Project from Beijing Economic-Technological Developmental Area","award":["JSYF2010150"],"award-info":[{"award-number":["JSYF2010150"]}]},{"name":"Beijing Health Guard Biotechnology Co., Ltd."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.pvr.2020.100209","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T12:09:43Z","timestamp":1605269383000},"page":"100209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16\/18\/58) in rhesus macaques"],"prefix":"10.1016","volume":"10","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shutian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt 10","key":"10.1016\/j.pvr.2020.100209_bib1","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1099\/0022-1317-73-10-2653","article-title":"Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations","volume":"73","author":"Van Ranst","year":"1992","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.pvr.2020.100209_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1006\/bbrc.1994.2533","article-title":"Analysis of short novel human papillomavirus sequences","volume":"204","author":"Tachezy","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.pvr.2020.100209_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/317638","article-title":"A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types","volume":"183","author":"Liaw","year":"2001","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.pvr.2020.100209_bib4","first-page":"453","article-title":"Diseases caused by human papillomaviruses (HPV)","volume":"7","author":"Handisurya","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.pvr.2020.100209_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin. Canc. Biol."},{"issue":"7","key":"10.1016\/j.pvr.2020.100209_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.pvr.2020.100209_bib7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"43","key":"10.1016\/j.pvr.2020.100209_bib8","doi-asserted-by":"crossref","first-page":"31803","DOI":"10.1074\/jbc.M706380200","article-title":"Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies","volume":"282","author":"Bishop","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.pvr.2020.100209_bib9","doi-asserted-by":"crossref","first-page":"e01104","DOI":"10.1128\/mBio.01104-14","article-title":"Maturation of the human papillomavirus 16 capsid","volume":"5","author":"Cardone","year":"2014","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.pvr.2020.100209_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jmbi.2000.4464","article-title":"Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1","volume":"307","author":"Chen","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"3\u20134","key":"10.1016\/j.pvr.2020.100209_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458166","article-title":"Human papillomavirus and the development of different cancers","volume":"150","author":"Gao","year":"2016","journal-title":"Cytogenet. Genome Res."},{"issue":"2","key":"10.1016\/j.pvr.2020.100209_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.str.2016.12.001","article-title":"Cryoelectron microscopy maps of human papillomavirus 16 reveal L2 densities and heparin binding site","volume":"25","author":"Guan","year":"2017","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.pvr.2020.100209_bib13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1128\/jvi.65.3.1578-1583.1991","article-title":"Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions","volume":"65","author":"Yaegashi","year":"1991","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.pvr.2020.100209_bib14","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.nano.2012.01.007","article-title":"Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles","volume":"8","author":"Zhao","year":"2012","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.pvr.2020.100209_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123944","article-title":"Identification of broad-genotype HPV L2 neutralization site for pan-HPV vaccine development by a cross-neutralizing antibody","volume":"10","author":"Wang","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pvr.2020.100209_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1746-1596-9-101","article-title":"Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein","volume":"9","author":"Wang","year":"2014","journal-title":"Diagn. Pathol."},{"issue":"25","key":"10.1016\/j.pvr.2020.100209_bib17","first-page":"136","article-title":"Analysis of cervical HPV infection of 1941 females in Qidong area in Jiangsu province","volume":"22","author":"Cai","year":"2015","journal-title":"China Modern Medicine"},{"issue":"11","key":"10.1016\/j.pvr.2020.100209_bib18","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/ijc.28896","article-title":"Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial","volume":"135","author":"Zhao","year":"2014","journal-title":"Int. J. Canc."},{"issue":"2","key":"10.1016\/j.pvr.2020.100209_bib19","first-page":"218","article-title":"Characteristic analysis of HPV infection in 5152 gynecological patients in some regions of Guangxi","volume":"37","author":"Wang","year":"2016","journal-title":"Internet J. Lab. Med."},{"issue":"11","key":"10.1016\/j.pvr.2020.100209_bib20","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/ijc.22195","article-title":"Do we need a different strategy for HPV screening and vaccination in East Asia?","volume":"119","author":"Miura","year":"2006","journal-title":"Int. J. Canc."},{"issue":"1","key":"10.1016\/j.pvr.2020.100209_bib21","first-page":"14","article-title":"Features on genotypes of human papillomavirus infection on patients with cervical cancer in Guangxi coastal areas","volume":"12","author":"Yang","year":"2011","journal-title":"Chin J Clin Obstet Gynecol"},{"issue":"Suppl 12","key":"10.1016\/j.pvr.2020.100209_bib22","doi-asserted-by":"crossref","first-page":"M30","DOI":"10.1016\/j.vaccine.2008.05.006","article-title":"Human papillomavirus infection and cervical cancer prevention in Japan and Korea","volume":"26","author":"Konno","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.pvr.2020.100209_bib23","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/sj.bjc.6605351","article-title":"Human papillomavirus infection in Beijing, People's Republic of China: a population-based study","volume":"101","author":"Zhao","year":"2009","journal-title":"Br. J. Canc."},{"issue":"1","key":"10.1016\/j.pvr.2020.100209_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.bjc.6603208","article-title":"Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study","volume":"95","author":"Dai","year":"2006","journal-title":"Br. J. Canc."},{"issue":"11","key":"10.1016\/j.pvr.2020.100209_bib25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/sj.bjc.6603450","article-title":"Human papillomavirus infection in Shenyang City, People's Republic of China: a population-based study","volume":"95","author":"Li","year":"2006","journal-title":"Br. J. Canc."},{"issue":"6","key":"10.1016\/j.pvr.2020.100209_bib26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ijc.22726","article-title":"Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation","volume":"121","author":"Wu","year":"2007","journal-title":"Int. J. Canc."},{"issue":"2","key":"10.1016\/j.pvr.2020.100209_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1258\/ijsa.2007.007113","article-title":"Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis","volume":"19","author":"Bao","year":"2008","journal-title":"Int. J. STD AIDS"},{"issue":"2","key":"10.1016\/j.pvr.2020.100209_bib28","first-page":"118","article-title":"Investigation on relationship between the papillomavirus type 58 (HPV58) infection and cervical cancer in China","volume":"10","author":"Liu","year":"1996","journal-title":"Chin. J. Exp. Clin. Virol."},{"issue":"10","key":"10.1016\/j.pvr.2020.100209_bib29","first-page":"941","article-title":"[Study on the distribution of human papillomavirus types in cervix among Chinese women: a meta-analysis]","volume":"28","author":"Bao","year":"2007","journal-title":"Zhonghua Liuxingbingxue Zazhi"},{"issue":"7","key":"10.1016\/j.pvr.2020.100209_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjose","year":"2007","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.pvr.2020.100209_bib31","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.7314\/APJCP.2013.14.7.4015","article-title":"Epidemiological features of Human Papillomavirus (HPV) infection among women living in Mainland China","volume":"14","author":"Li","year":"2013","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"3","key":"10.1016\/j.pvr.2020.100209_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11684-010-0095-5","article-title":"HPV prevalence and genotyping in the cervix of Chinese women","volume":"4","author":"Wang","year":"2010","journal-title":"Front. Med. China"},{"issue":"3","key":"10.1016\/j.pvr.2020.100209_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","article-title":"In vivo mechanisms of vaccine-induced protection against HPV infection","volume":"8","author":"Day","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.pvr.2020.100209_bib34","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.vaccine.2011.01.001","article-title":"HPV16\/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection","volume":"29","author":"Kemp","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.pvr.2020.100209_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1086\/597308","article-title":"Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types","volume":"199","author":"Herrero","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pvr.2020.100209_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","article-title":"Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.pvr.2020.100209_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.pvr.2020.100209_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"issue":"37","key":"10.1016\/j.pvr.2020.100209_bib39","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.pvr.2020.100209_bib40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","article-title":"HPV vaccine cross-protection: highlights on additional clinical benefit","volume":"130","author":"De Vincenzo","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"39","key":"10.1016\/j.pvr.2020.100209_bib41","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.pvr.2020.100209_bib42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pvr.2020.100209_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pvr.2017.02.005","article-title":"A novel trivalent HPV 16\/18\/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model","volume":"3","author":"Yin","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.pvr.2020.100209_bib44","first-page":"445","article-title":"Generation of HPV pseudovirions using transfection and their use in neutralization assays","volume":"119","author":"Buck","year":"2005","journal-title":"Methods Mol. Med."},{"year":"2008","series-title":"[Yi Jia Bing Du Wei Ji Chu De Ren Ru Tou Liu Bing Du (HPV) Zhong He Kang Ti Jian Ce Fang Fa He Dong Wu Gan Ran Mo Xing De Jian Li Ji Chu Bu Ying Yong]","author":"Wu","key":"10.1016\/j.pvr.2020.100209_bib45"},{"issue":"12","key":"10.1016\/j.pvr.2020.100209_bib46","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum. Vaccine"},{"issue":"10","key":"10.1016\/j.pvr.2020.100209_bib47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.pvr.2020.100209_bib48","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.pvr.2020.100209_bib49","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2011.09.021","article-title":"Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera","volume":"29","author":"Draper","year":"2011","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.pvr.2020.100209_bib50","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"issue":"9518","key":"10.1016\/j.pvr.2020.100209_bib51","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pvr.2020.100209_bib52","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J. Infect. Dis."}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852120301361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852120301361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:03:43Z","timestamp":1762513423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852120301361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"alternative-id":["S2405852120301361"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2020.100209","relation":{},"ISSN":["2405-8521"],"issn-type":[{"type":"print","value":"2405-8521"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16\/18\/58) in rhesus macaques","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2020.100209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100209"}}